Skip to content
by Legal Desire
SIGN IN GO PRO
17 June 2021

Latham & Watkins Advises the Underwriters in Lyell Immunopharma’s US$425 Million IPO

Capital Markets & IPO Healthcare & Life Sciences Expected to close United States

Advising firms

Latham & Watkins LLP
Underwriters acting for underwriters

Deal team

15 lawyers named
LawyerFirmSeniorityPracticeOffice
Brian Cuneo Lead Latham & Watkins LLP Partner capital markets Bay Area
Shayne Kennedy Lead Latham & Watkins LLP Partner capital markets Orange County
Raul Gonzalez Latham & Watkins LLP Associate capital markets Bay Area
Melinda Vanderburg Latham & Watkins LLP Associate capital markets Bay Area
Elizabeth Richards Latham & Watkins LLP Partner FDA regulatory matters Washington, D.C.
Nathan Beaton Latham & Watkins LLP Associate FDA regulatory matters Washington, D.C.
Lacey Henry Latham & Watkins LLP Associate FDA regulatory matters New York
Betty Pang Latham & Watkins LLP Counsel healthcare regulatory matters Bay Area
Judith Hasko Latham & Watkins LLP Partner intellectual property matters Bay Area
Peggy Ni Latham & Watkins LLP Associate intellectual property matters Bay Area
Heather Deixler Latham & Watkins LLP Counsel data privacy matters Bay Area
Grace Lee Latham & Watkins LLP Partner tax matters Bay Area
Gregory Conyers Latham & Watkins LLP Associate tax matters Bay Area
James Metz Latham & Watkins LLP Partner benefits and compensation matters Bay Area
Samantha Voutyras Latham & Watkins LLP Associate benefits and compensation matters Chicago

Stated terms

Stated value
USD 425m (US$425 million)
What the figure measures
Issue size
Client
Not stated
Counterparties
Lyell Immunopharma, Inc. (Issuer)